Oramed Pharmaceuticals Inc.

www.oramed.com

High-Tech Company
Public Company

(NASDAQ CM: ORMP), (Frankfurt Stock Exchange: OJU), (TASE: ORMP)

TECH VERTICALS

Biotechnology, Diabetes, Life Sciences, MedTech, Pharmaceuticals, Protein, Therapeutics

General Data

Sector	Biomed
Company Stage:	R&D
Established	2006
Number of Employees	16
Employees in Israel	10
Reg. Number:	abCDe

DESCRIPTION

Oramed Pharmaceuticals has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. Oramed has an experienced management team with many years of business and pharmaceutical experience, and is backed by world-class scientific experts. From the company's inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an orally ingestible insulin capsule, ORMD-0801, and an oral GLP-1 analog (exenatide) capsule, ORMD-0901.

TECHNOLOGY

Oramed Pharmaceuticals’ POD™ (Protein Oral Delivery) technology has been designed to (1) protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and (2) to enhance their absorption across the intestinal wall.

The active protein is encapsulated in a capsule that features a highly protective coating that remains intact in the most acidic segments of the gut, as well as enzymatic support provided by specialized protease inhibitors.

Drug availability is further secured by an absorption enhancer supplement that facilitates protein passing across the intestinal barrier.

By preventing protein-drug breakdown in the gastrointestinal tract and promoting its crossing the small intestine, this breakthrough solution brings oral protein-drug delivery significantly closer to a reality.

Products and Phases

Product	Phase
ORMD 0801 – Oral Insulin Capsule for T2DM	Phase III
Diabetes is a chronic condition characterized by hyperglycemia, or elevated blood glucose levels. If left untreated, diabetes may lead to complications such as cardiovascular disease, chronic renal failure, retinopathy and amputations. Type 2 diabetes (T2DM) is a progressive disease characterized by impaired ß cell function and insulin resistance. There are over 340 million type 2 diabetics worldwide with an economic burden of close to half a trillion dollars annually. Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream. Oramed’s oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications.
ORMD 0801 – Oral Insulin Capsule for T1DM	Phase II
Type I diabetes mellitus (T1DM), also known as insulin-dependent diabetes, is an autoimmune disease where the immune system attacks and destroys pancreatic ß cells. Hence little or no insulin is produced to facilitate the uptake of glucose. Clinically, T1DM is marked by fluctuations in glycemic readings and poor glycemic control. Oramed’s oral insulin capsule (ORMD-0801) is anticipated for use as a complementary agent to insulin injections in the treatment of T1DM. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM.
ORMD 0901 – Oral GLP-1 for T2DM	Phase I
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss. Oramed’s oral GLP-1 capsule based on the company’s PODTM technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.

	TARGET MARKETS
	Diabetes Patients.

	BUSINESS MODEL
	B2C

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm
abC Defghij	Patent Attorneys

REMARKS

Date	Remark
08/03/2006	Integrated Security Technologies acquired its patent and IP from Hadasit Medical Services & Development Ltd. and changed its to Oramed.

CONTACT INFO

Expand / Collapse All

Main Address: Jerusalem, Israel

Address	2/4 Givat Ram, Hi-Tech Park, Hi-Tech Park
POB	39098
City	Jerusalem
Country	Israel
Zip	9139002

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: New York, United States

Address	1185 Avenue of the Americas, Suite 228
City	New York
State/Province	NY
Country	United States
Zip	10036

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Nadav Kidron	CEO, President & Co-Founder	Trendlines Venture (Senior Advisor)
Dr. Miriam Kidron	Chief Scientific Officer & Co-Founder
Mr. Josh Hexter	Chief Operating & Business Officer	Brainsway (Chief Business Officer)
Mr. Avi Gabay	CFO	Quantum Machines (VP, Finance)
Dr. Hanoch Bar-On	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	Secretary, Oramed Pharmaceuticals
abC Defghij	Board Member	CEO & Co-Founder, Oramed
abC Defghij	Board Member	CSO & Co-Founder, Oramed
abC Defghij	Independent Director	Co-Founder, The Daily Wire
abC Defghij	Independent Director	Managing Director, Merck Life Science Israel
abC Defghij	Board Member	Neurosurgeon, Memorial Healthcare System
abC Defghij	Board Member	Mr. Yehuda Reznick has been an Oramed director since April 2024. He served as an audit partner at Kesselman & Kesselman CPA, a member of PricewaterhouseCoopers International Limited, from 1999 until 2014. Prior to joining Kesselman & Kesselman, he was a tax and audit partner at Shachak, Peer Reznick CPA for sixteen years. Mr. Reznick currently serves on the board of directors of Oravax Medical Inc., an affiliate of the Company. Since 2019, Mr. Reznick has also served on the board of directors of Hiron-Trade Investments & Industrial Buildings Ltd (TASE: HRON). Mr. Reznick previously served on the board of directors of Bonus Biogroup Ltd (OTC: BBIXF) from 2017 to 2023.

Mergers & Acquisitions

Round

Date

Stage

Amount

Valuation

Reverse Merger

Mar. 08, 2006

abCDe

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Nov. 03, 2021	Third Public Offering	NASDAQ CM	abCDe	abCDe	Registered Direct Offering
Feb. 27, 2020	Second Public Offering	NASDAQ CM	abCDe	abCDe
Jul. 06, 2017	Dual Listing	TASE	abCDe	abCDe
Feb. 11, 2013	Listing	NASDAQ CM	abCDe	abCDe
Jul. 14, 2006	Listing	Frankfurt Stock Exchange	abCDe	abCDe

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Jul. 06, 2018

R&D

abCDe

PIPE

Nov. 30, 2015

R&D

abCDe

PIPE

Dec. 03, 2014

R&D

abCDe

PIPE

Dec. 25, 2013

R&D

abCDe

PIPE

Jul. 14, 2013

R&D

abCDe

PIPE

Dec. 12, 2012

R&D

abCDe

PIPE

Mar. 09, 2011

R&D

abCDe

PIPE

Jul. 15, 2008

R&D

abCDe

PIPE

Aug. 06, 2007

R&D

abCDe

Seed

Apr. 01, 2002

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Dec. 23, 2010

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Aug. 04, 2009

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

	PORTFOLIO COMPANIES

Current Portfolio Companies (2)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

DNA Biomedical Solutions Ltd.

N/A

Other

01/11/2010

N/A

Lifeward

PIPE

25/03/2026

N/A

$10m

Exits (1)

Company Name		Exit Type	Date Announced	Amount	Remarks
abC Defghij		IPO	28/06/2018	abCDe

Last Updated:	abCDe
IVC Number:	abCDe